Nonetheless, little is known about the influence of tyrosine kinase inhibitors (TKIs) in immune responses derived from COVID-19 vaccines in NSCLC patients with EGFR and ALK alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.